Detalhe da pesquisa
1.
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Haematologica
; 102(4): 765-772, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28011903
2.
Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Ann Hematol
; 96(2): 253-259, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27900446
3.
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 17(8): 1081-1093, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27345636
4.
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
Blood
; 124(14): 2196-202, 2014 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25143487
5.
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
Blood
; 122(7): 1137-43, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23843495
6.
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
Front Immunol
; 14: 1085893, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37559718
7.
Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.
Blood
; 126(24): 2646-9, 2015 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26447188
8.
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
Leukemia
; 34(2): 522-532, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31462735
9.
Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.
J Clin Oncol
; 31(23): 2920-6, 2013 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23835715
10.
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.
J Clin Oncol
; 31(23): 2912-9, 2013 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23835718
11.
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
J Clin Oncol
; 26(28): 4579-86, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18662969